TY - JOUR
T1 - Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT, p16INK4a, and p19ARF genes in nasopharyngeal carcinoma
AU - Ko, Jenq Yuh
AU - Lee, Tso Ching
AU - Hsiao, Chin Fu
AU - Lin, Guan Lu
AU - Yen, Sang Hue
AU - Chen, Kuang Y.
AU - Hsiung, Chao A.
AU - Chen, Pei Jer
AU - Hsu, Mow Ming
AU - Jou, Yuh Shan
PY - 2002/4/1
Y1 - 2002/4/1
N2 - BACKGROUND. Recurrent deletion on a chromosomal location in tumor cells can be detected by frequent allelic loss and generally is considered to be an indication of the existence of a tumor suppressor gene (TSG) in the region. In the current study, using fluorescent-labeled, high-density microsatellite markers for allelotyping, the authors pinpointed three minimal deleted regions (MDRs) and screened mutations of putative TSGs on chromosomes 3, 9, and 11 in nasopharyngeal carcinoma (NPC) cases occurring in Taiwan. METHODS. A total of 133 informative microsatellite markers were used on chromosomes 3, 9, and 11 with an average marker density of 4 centimorgans (cM) for the allelotyping of genomic DNAs isolated from NPC tissues and their corresponding lymphocytes in 48 patients. The correlation between allelic loss and the clinicopathologic parameters of NPC tissues was examined. In addition, putative TSGs including FHIT, p16INK4a, and p19ARF were selected for mutation screening to investigate their potential participation in NPC tumorigenesis. RESULTS. Of 3787 informative allelotyping data, 25 frequent allelic losses (or loss of heterozygosity [LOH]) in 13 cytogenetic loci were identified based on a deletion frequency that was greater than the average of allelic loss on that particular chromosome. Several significant associations were determined after statistical analysis of the correlation between allelic loss and clinicopathologic parameters. The allelic losses by D9S318 and D11S1304 were associated with N2/N3 (P= 0.035 and P = 0.005, respectively), and those by D9S905 and D11S1304 were associated with grouped American Joint Committee on Cancer (AJCC) Stage III/IV samples (P = 0.022 and P = 0.017, respectively) of NPC tissues. In addition, three MDRs were revealed on 3p25.3-24.1 (< 19 cM), 3p23-21.31 (< 9 cM), and 11q22.1-23.2 (< 8 cM). To examine somatic mutations in previously reported TSGs located near these frequent LOH loci, three candidate genes, p16INK4a, p19ARF, and FHIT, were analyzed. Point mutations in the coding region of FHIT and in the intron 1 splicing acceptor site of both p16INK4a and p19ARK were detected in NPC cell lines. Sequence analysis of both p16INK4a and p19ARK transcripts revealed that the point mutation resulted in skipping of exon 2 and the generation of shorter transcripts. CONCLUSIONS. High-density allelotyping permitted the discovery of 3 MDRs on 3p25.3-24.1 (< 19 cM), 3p23-21.31 (< 9 cM), and 11q22.1-23.2 (< 8 cM) and a correlation was determined between allelic loss and clinicopathologic parameters of NPC tissues. More important, one somatic mutation in NPC cell lines on the intron 1/exon 2 splicing acceptor site of the INK4a/ARF locus was found to result in exon 2 skipping both p16INK4a and p19ARF transcripts, which presumably inactivates the functions of both the p16INK4a and p19ARF proteins.
AB - BACKGROUND. Recurrent deletion on a chromosomal location in tumor cells can be detected by frequent allelic loss and generally is considered to be an indication of the existence of a tumor suppressor gene (TSG) in the region. In the current study, using fluorescent-labeled, high-density microsatellite markers for allelotyping, the authors pinpointed three minimal deleted regions (MDRs) and screened mutations of putative TSGs on chromosomes 3, 9, and 11 in nasopharyngeal carcinoma (NPC) cases occurring in Taiwan. METHODS. A total of 133 informative microsatellite markers were used on chromosomes 3, 9, and 11 with an average marker density of 4 centimorgans (cM) for the allelotyping of genomic DNAs isolated from NPC tissues and their corresponding lymphocytes in 48 patients. The correlation between allelic loss and the clinicopathologic parameters of NPC tissues was examined. In addition, putative TSGs including FHIT, p16INK4a, and p19ARF were selected for mutation screening to investigate their potential participation in NPC tumorigenesis. RESULTS. Of 3787 informative allelotyping data, 25 frequent allelic losses (or loss of heterozygosity [LOH]) in 13 cytogenetic loci were identified based on a deletion frequency that was greater than the average of allelic loss on that particular chromosome. Several significant associations were determined after statistical analysis of the correlation between allelic loss and clinicopathologic parameters. The allelic losses by D9S318 and D11S1304 were associated with N2/N3 (P= 0.035 and P = 0.005, respectively), and those by D9S905 and D11S1304 were associated with grouped American Joint Committee on Cancer (AJCC) Stage III/IV samples (P = 0.022 and P = 0.017, respectively) of NPC tissues. In addition, three MDRs were revealed on 3p25.3-24.1 (< 19 cM), 3p23-21.31 (< 9 cM), and 11q22.1-23.2 (< 8 cM). To examine somatic mutations in previously reported TSGs located near these frequent LOH loci, three candidate genes, p16INK4a, p19ARF, and FHIT, were analyzed. Point mutations in the coding region of FHIT and in the intron 1 splicing acceptor site of both p16INK4a and p19ARK were detected in NPC cell lines. Sequence analysis of both p16INK4a and p19ARK transcripts revealed that the point mutation resulted in skipping of exon 2 and the generation of shorter transcripts. CONCLUSIONS. High-density allelotyping permitted the discovery of 3 MDRs on 3p25.3-24.1 (< 19 cM), 3p23-21.31 (< 9 cM), and 11q22.1-23.2 (< 8 cM) and a correlation was determined between allelic loss and clinicopathologic parameters of NPC tissues. More important, one somatic mutation in NPC cell lines on the intron 1/exon 2 splicing acceptor site of the INK4a/ARF locus was found to result in exon 2 skipping both p16INK4a and p19ARF transcripts, which presumably inactivates the functions of both the p16INK4a and p19ARF proteins.
KW - FHIT
KW - Loss of heterozygosity (LOH)
KW - Nasopharyngeal carcinoma (NPC)
KW - p16
KW - p19
UR - http://www.scopus.com/inward/record.url?scp=84983724119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983724119&partnerID=8YFLogxK
U2 - 10.1002/cncr.10406
DO - 10.1002/cncr.10406
M3 - Article
C2 - 11932901
AN - SCOPUS:84983724119
SN - 0008-543X
VL - 94
SP - 1987
EP - 1996
JO - Cancer
JF - Cancer
IS - 7
ER -